Member Info for Bobbler

Covid research on time, clearly this has been their main focus.

"We look forward to reporting the results from the UKRI-funded studies that are investigating the potential of SDC-1801 to reduce the excessive inflammatory response seen in severe Covid-19. Positive results, that confirm our early findings, will enable us to explore further opportunities to develop SDC-1801 in this indication, in parallel with our broader autoimmune programme."

Below paragraph from UNHCR report. $9.2trillion in GDP losses! Minimum 80% of world population won’t be vaccinated by 2022. Covid will just keep on circulating. A blockbuster treatment really is going to be worth a staggering amount.

However , COVAX is only intended to cover 20% of the global population– the most vulnerable in lower-income countries – by the end of 2021 and it is not yet clear if it will meet this target. Meanwhile studies show that if we focus only on vaccinating our own populations, the world risks global GDP losses of up to $9.2 trillion (with half of that cost being incurred by high income countries) this year alone.

https://www.unhcr.org/news/press/2021/5/60a7fc9b4/statement-no-one-safe-safe-need-global-response-covid-19.html

Hi Potnak, i agree I believe it will be a very turbulent time over the next few weeks. Unfortunately, my gut feeling is, that a lot of the recent gain is due to Covid speculation. Although it is a side show as far as SAR is concerned, if a negative RNS lands I think the SP will hit the pre-Covid level, anywhere between 0.3-1p.

Having said that I’m not selling, like most of the LTH I accept the risk/reward scenario. Ideally we could do with a positive SRA737 RNS prior to any Covid announcement, which would hopefully soften the blow if a negative Covid RNS was to follow.

It’s certainly a case of place your betts and hope Lady Luck is on our side.

Condolences SOG.

Me 2

Does not sound like a great choice of drug. Desperation in India I fear.

Baricitinib for COVID-19: a suitable treatment?

In conclusion, we believe that, beyond the intriguing opportunity to directly block the penetration of SARS-CoV-2 into the cell, the use of baricitinib in susceptible patients with ongoing pneumonia associated with COVID-19 should be considered with extreme caution.
We declare no competing interests.

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30262-0/fulltext

Thoth- I recall you mentioned the wellcome trust a few weeks ago. Not sure if you’re aware, but the study that was cited in Nature, Highlighting tyk2 as a Covid target for treatment : Genetic mechanisms of critical illness in COVID-19 and conducted by the GenOMICC consortium, was funded by the wellcome trust.

https://pubmed.ncbi.nlm.nih.gov/33542028/

Reads well ......

Recently, TYK2 has emerged as a target of choice for the treatment of autoimmune diseases and severe COVID-19 with an optimum balance between efficacy and safety, based on observations from human genetics studies and clinical outcomes of several agents targeting cytokine pathways for which TYK2 plays an essential role.

Pan-acting small-molecule JAK inhibitors were approved for the treatment of rheumatoid arthritis and ulcerative colitis. However, their limited selectivity among JAK members have led to undesirable side effects, driving a search toward specific JAK inhibitors.

Morning SOG sepsis and Covid appear to be a serious problem. Imagine if SAR could kills 2 birds with the one stone!

https://www.nihr.ac.uk/news/nihr-funded-trial-examines-antibiotic-treatment-for-sepsis-in-covid-19/26009

Hi Num. looks like India is ploughing ahead with baricitinib and Bangladesh is conducting a high dose trial. I believe recommend dose 2mg per day and there going at 8mg

https://www.google.co.uk/amp/s/www.moneycontrol.com/news/business/companies/how-natco-pharma-put-us-drug-giant-eli-lilly-under-pressure-for-covid-19-drug-through-compulsory-licensing-filing-6854771.html/amp

https://www.google.co.uk/amp/s/www.docwirenews.com/abstracts/impact-of-high-dose-of-baricitinib-in-severe-covid-19-pneumonia-a-prospective-cohort-study-in-bangladesh/amp/

However it’s n Not recommended with known active TB, In fact, no country has a higher TB burden than India, which accounts for a quarter of the 10 million global TB cases and 1.4 million TB deaths each year. Bangladesh I believe is in the top 3 for TB.

Desperate times, clearly a market for a cleaner alternative.

Reference to Tyk2 -review of Baricitinib in COVID-19

• Exaggerated immune response is a well-recognised part of the COVID-19 syndrome among people requiring hospitalisation
• Significant interest in treatments that modulate this response

https://www.recoverytrial.net/files/recovery-collaborators-meeting-2021-01-05.pdf

Generic manufacturing of any seriously effective drug seems to be where the majority of poorer nations will go.

https://www.google.co.uk/amp/s/m.timesofindia.com/business/india-business/natco-rolls-out-baricitinib-ahead-of-approval-for-patent-waiver/amp_articleshow/82442841.cms

EQS is a company. Look at the bottom of the “not an RNS”.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.
Software company.
EQS Group is a leading international provider of regulatory technology (RegTech) in the fields of corporate compliance and investor relations.

This “News” has as much gravitas as all the other posts on here. It’s just an opinion written by a third party. There is nothing in it, that hasn’t already been posted on here by a number of well researched posters. Crazy

It isn’t an RNS, looks like a third party marketing setup.

Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.

Fadec, you appear to be suggesting that SAR have missed the boat, it’s all to late and COVID is a thing of the past. Couple of points. Why has the U.K. Gov in the past few weeks launched the Therapeutics task force if as you say it’s all but passed. I agree the U.K. will have vaccinated a large percentage of the population very soon. However this is not the case for the majority of the world’s poorest nations. I don’t think COVID was a freak of nature. Mankind continues to cross the natural barriers that nature has created to prevent animal hosted diseases jumping species (I.e deforestation of the Amazon). This activity shows no sign of stopping, poverty and greed are the drivers. Therefore these types of diseases will continue to cross over. Maybe only 1 virus in 100 will be successful at attacking mankind. But as has been seen one is one to many.

Abstract from this article

Why mRNA COVID-19 vaccines might unlock the key to treating cancer and other deadly diseases

https://beta.ctvnews.ca/national/coronavirus/2021/4/29/1_5407405.html

Both Pfizer and Moderna have said they’re planning to use the technology to develop a vaccine against influenza. Moderna recently announced that it was developing mRNA vaccine candidates for the seasonal flu, HIV, and the Nipah virus, following the success of its COVID-19 vaccine.
BioNTech, which partnered with Pfizer for the COVID-19 vaccine, is already researching how mRNA technology might be used to treat autoimmune diseases, such as MS, in mouse trials.
Morris said for autoimmune diseases, in which the immune system attacks the body, the thinking is that the mRNA could teach the immune system to “calm down” or be less reactive against the body’s cells.
“It's very, very early, obviously, in this technology, but the potential for this to affect patients with autoimmune diseases as well is I think, you know, extraordinary,” Morris said.

I agree T2. My feeling is when Sierra asked for a change of the terms they already had (have) some form of deal being floated and have used it to renegotiate better financial terms for their end. Tim was pretty clear when he said there is no point in them renegotiating the terms if they don't plan to move forward (or words to that effect). I know people criticise Tim because he does a lot of 'humming and harring' . Personally i think its simply because he is very conscious of making sure he doesn't fall foul of any confidentiality agreements.

Just had another listen to yesterday’s presentation. John says they’re looking to do a deal from CTA onwards. Guessing June could be an interesting month.